背景:我们研究了特定生物标志物的效用-即,c末端端肽(CTX),n-端肽(NTX),脱氧吡啶啉(DPD),和抗酒石酸酸性磷酸酶(TRAP)-与常规诊断方法相比。我们认为这些新型生物标志物在诊断中具有重要价值,治疗,和监测骨质疏松症。
方法:这项研究进行了三年,从2020年1月1日至2023年1月1日。我们共纳入520名年龄在50岁或以上的患者,这些患者被诊断患有骨质疏松症。接受类固醇治疗的患者,已知会导致骨质疏松症,被排除在研究之外。此外,我们根据与骨质疏松诊断相关的人口学特征,精心选择并匹配了由500例患者组成的对照组.这一细致的选择过程导致了一个由1,020名患者组成的全面队列。在整个研究过程中,对患者进行为期1年的密切监测,以追踪病理性骨折的发生情况并评估其总体预后.
结果:由于我们严格的调查,我们确认了CTX,NTX,DPD,和TRAP作为关键的生物标志物,在评估骨骼健康中起着至关重要的作用,监测治疗效果,并在骨质疏松症的背景下检测病理性骨折。
结论:我们的研究强调了这些生物标志物在推进骨孔病的诊断和治疗中的意义。为疾病的进展和治疗结果提供有价值的见解。
BACKGROUND: We investigated the utility of specific biomarkers-namely, c-terminal telopeptide (CTX), n-telopeptide (NTX), deoxypyridinoline (DPD), and tartrate-resistant acid phosphatase (TRAP)-compared to conventional diagnostic methods. We hy-pothesized that these novel biomarkers could hold substantial value in the diagnosis, treatment, and monitoring of osteoporosis.
METHODS: The study was conducted over a three-year period, from January 1, 2020, to January 1, 2023. We enrolled a total of 520 patients aged 50 years or older who had been diagnosed with osteoporosis. Patients undergoing steroid treatments, which are known to contribute to osteoporosis, were excluded from the study. Additionally, we carefully selected and matched a control group consisting of 500 patients based on demographic characteristics relevant to the diagnosis of osteoporosis. This meticulous selection process resulted in a comprehensive cohort comprising 1,020 patients. Throughout the study, patients were closely monitored for a duration of one year to track the occurrence of pathological fractures and assess their overall prognosis.
RESULTS: As a result of our rigorous investigation, we identified CTX, NTX, DPD, and TRAP as pivotal biomarkers that play a crucial role in evaluating bone health, monitoring treatment effectiveness, and detecting pathological fractures in the context of osteoporosis.
CONCLUSIONS: Our study underscores the significance of these biomarkers in advancing the diagnosis and management of osteo-porosis, offering valuable insights into the disease\'s progression and treatment outcomes.